# BULLSEYE (NCT04443062)

> Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: 177Lu-PSMA-617
- Indication: oligometastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04443062
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Radboud University Medical Center
- Conditions: Prostate Cancer
- Interventions: 177Lu-PSMA-617
- Enrollment: 58
- Primary outcome: To compare the fraction of patients that have disease progression (and meet EOT 1) criteria within 6 months in a group of patients that are treated with 177Lu-PSMA and a group that follows the current standard of care.
- Primary outcome: A second primary aim is to compare the two arms for the time to disease progression and meeting EOT 1 criteria.

## Indexed commentary on BULLSEYE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 28 posts on X
- 5 YouTube videos
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bullseye-nct04443062

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04443062", "email": "<work email>"}; the inbox owner confirms by the emailed link.